We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.09%: What You Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $66.90, moving -0.09% from the previous trading session. This change was narrower than the S&P 500's 0.3% loss on the day. At the same time, the Dow lost 0.2%, and the tech-heavy Nasdaq lost 0.11%.
Prior to today's trading, shares of the company had gained 14.77% over the past month. This has outpaced the Medical sector's loss of 0.32% and the S&P 500's loss of 0.62% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. On that day, CRISPR Therapeutics AG is projected to report earnings of -$2.23 per share, which would represent a year-over-year decline of 123.62%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.23 million, down 99.53% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$8.98 per share and revenue of $187.03 million. These results would represent year-over-year changes of -291.06% and -79.56%, respectively.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.11% lower within the past month. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 103, which puts it in the top 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Stock Moves -0.09%: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $66.90, moving -0.09% from the previous trading session. This change was narrower than the S&P 500's 0.3% loss on the day. At the same time, the Dow lost 0.2%, and the tech-heavy Nasdaq lost 0.11%.
Prior to today's trading, shares of the company had gained 14.77% over the past month. This has outpaced the Medical sector's loss of 0.32% and the S&P 500's loss of 0.62% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. On that day, CRISPR Therapeutics AG is projected to report earnings of -$2.23 per share, which would represent a year-over-year decline of 123.62%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.23 million, down 99.53% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$8.98 per share and revenue of $187.03 million. These results would represent year-over-year changes of -291.06% and -79.56%, respectively.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.11% lower within the past month. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 103, which puts it in the top 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.